Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

被引：1

作者：

Kraeber-Bodere, Francoise ^{[1
]}

Maisonneuve, Herve ^{[2
]}

Lamy, Thierry ^{[3
]}

Le Gouill, Steven ^{[4
]}

Deconninck, Eric ^{[5
]}

Pallardy, Amandine ^{[1
]}

Bodet-Milin, Caroline ^{[1
]}

Milpied, Noel ^{[6
]}

Morineau, Nadine ^{[7
]}

Foussard, Charles ^{[8
]}

Gastinne, Thomas ^{[4
]}

Gressin, Remy ^{[9
]}

Toumilhac, Olivier ^{[10
]}

Gyan, Emmanuel ^{[11
]}

Moreau, Anne

Chauvet, Alain Faivre ^{[1
]}

Cazeau, Anne-Laure ^{[12
]}

Garin, Etienne

Vuillez, Jean-Philippe ^{[13
]}

Chatal, Jean-Francois ^{[14
]}

Harousseau, Jean-Luc ^{[15
]}

Moreau, Philippe ^{[4
]}

Wegener, William ^{[16
]}

Goldenberg, David ^{[17
]}

Soubeyran, Pierre ^{[18
]}

机构：

[1] CHU Nantes, Nucl Med Serv, F-44035 Nantes 01, France

[2] CH La Roche Yon, La Roche Sur Yon, France

[3] CHU Rennes, Hematol Dept, Rennes, France

[4] CHU Nantes, Hematol Dept, F-44035 Nantes 01, France

[5] Hop Jean Minjoz, F-25030 Besancon, France

[6] Hop Haut Leveque, Pessac, France

[7] Ctr Catherine Sienne, Nantes, France

[8] CHU Angers, Serv Malad Sang, Angers, France

[9] CHU Grenoble, INSERM, Inst Albert Bonniot, U823, F-38043 Grenoble, France

[10] CHU Clermont Ferrand, Serv Hematol Adultes & Therapie Cellulaire, Clermont Ferrand, France

[11] CHRU Tours, Serv Hematol & Therapie Cellulaire, Tours, France

[12] Inst Bergonie, Nucl Med Serv, Bordeaux, France

[13] CHU Michallon, Nucl Med Serv, Grenoble, France

[14] GIP ARRONAX, St Herblain, France

[15] Rene Gauducheau Canc Ctr, St Herblain, France

[16] Immunomed Inc, Clin Res, Morris Plains, NJ USA

[17] Ctr Mol Med & Immunol, Belleville, NJ USA

[18] Inst Bergonie, Bordeaux, France

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.2875.2875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1184 / 1184

页数：1

共 48 条

[31] Conventional and hematopoietic stem-cell-supported radioimmunotherapy (RAIT) with humanized 90Y-LL2 (90Y-hLL2) anti-CD22 monoclonal antibody (MAb) in NHL patients who failed high-dose chemotherapy (HDC).
Juweid, M
Matthies, A
Alavi, A
Shuster, S
Dawns, L
Luger, S
Saleh, S
Hajjar, G
Sharkey, RM
Rubin, A
Stadtmauer, E
Goldenberg, DM
BLOOD, 1999, 94 (10) : 174A - 174A
[32] High cure rate of adult Burkitt's and other high grade NHL by the anti-CD22 epratuzumabat high cumulative 90Y doses combination of short intensive chemotherapy cycles with rituximab
Hoelzer, D.
Hiddemann, W.
Baumann, A.
Doehner, H.
Duehrsen, U.
Fietkau, R.
Hansmann, M.-L.
Huettmann, A.
Irmer, S.
Kaun, S.
Kneba, M.
Reichle, A.
Schmid, M.
Schmidt-Wolf, I.
Thiel, E.
Walewski, J.
Goekbuget, N.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
[33] Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).
Hamlin, Paul A., Jr.
Rodriguez, Maria Alma
Noy, Ariela
Portlock, Carol S.
Straus, David
McLaughlin, Peter
Pro, Barbara
Fayad, Luis
Hagemeister, Frederick
Wegner, Brett
Dumitrescu, Otilia
Tasker, Neetha Pandit
Moskowitz, Craig H.
Zelenetz, Andrew D.
BLOOD, 2010, 116 (21) : 748 - 749
[34] Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab
Berinstein, Neil L.
Pennell, Nancy M.
Cussen, Mary-Anne
Imrie, Kevin R.
Piliotis, Eugenia
Buckstein, Rena
Ghorab, Zeina
Miles, Ellen Anne
Chesney, Alden E.
Cheung, Matthew
BLOOD, 2012, 120 (21)
[35] CONSOLIDATION TREATMENT WITH Y90-IBRITUMOMAB TIUXETAN AFTER R-CHOP INDUCTION IN HIGH-RISK PATIENTS WITH FOLLICULAR LYMPHOMA (FL) (GOTEL-FL1LC): A MULTICENTRIC, PROSPECTIVE STUDY
Provencio Pulla, M.
Cruz Mora, M. A.
Gomez Codina, J.
Quero, C.
Llanos, M.
Garcia Arroyo, F. R.
De La Cruz, L.
Guma, J.
Delgado, J. R.
Rueda, A.
ANNALS OF ONCOLOGY, 2012, 23 : 351 - 351
[36] Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Won Seog
Lee, Won-Sik
Do, Young Rok
Oh, Sung Yong
Kim, Min Kyoung
Mun, Yeung-Chul
Shin, Ho-Jin
Kwak, Jae-Yong
Kang, Hye Jin
Won, Jong Ho
Kwon, Jung Hye
Park, Eunkyung
Suh, Cheolwon
Yang, Deok-Hwan
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (06) : 504 - 510
[37] Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma
Yang, Deok-Hwan
Kim, Won Seog
Suh, Cheolwon
Kwak, Jae-Yong
Jung, Joo-Sep
Kim, Sung Hyun
Kim, Jin Seok
Lee, Je-Jung
Kim, Hyeoung-Joon
BLOOD, 2009, 114 (22) : 1444 - 1444
[38] Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y90 (IT-Y90) in non-pretreated patients age 65 to 80 with CD20+diffuse large B-cell lymphoma (DLBCL)
Peyrade, Frederic
Lepeu, Gerard
Gal, Jocelyn
Fruchart, Christophe
Coso, Diane
Bologna, Serge
Provencio, Mariano
Kaphan, Regis
Sohn, Claudine
Audhuy, Bruno
Codina, Gomez
Thyss, Antoine
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39] First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan (90Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma
Pennell, Nancy M.
Cheung, Matthew
Hicks, Lisa K.
Piliotis, Eugenia
Imrie, Kevin R.
Buckstein, Rena
Davidson, Cindy
Cussen, Mary-Anne
Ghorab, Zeina
Chesney, Alden
Berinstein, Neil L.
BLOOD, 2011, 118 (21) : 1161 - 1161
[40] Conventional and hematopoietic stem-cell-supported (HSC-supported) radioimmunotherapy of relapsed/refractory non-Hodgkin's lymphoma (NHL) with 90Y-humanized LL2 (90-hLL2) anti-CD22 monoclonal antibody (MAb).
Juweid, M
Matthies, A
Schuster, SL
Stadtmauer, EA
Czuczman, M
Lamonica, D
Pourdehnad, M
Sharkey, RM
Alavi, AA
Goldenberg, DM
JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 31P - 31P

← 1 2 3 4 5 →